Developing anti-CD19 antibody-based combinations in lymphoma
Mené dans 10 pays sur 156 patients atteints d’un lymphome diffus à grandes cellules B réfractaire ou récidivant et inéligibles à une greffe autologue de cellules souches, cet essai de phase II évalue l’efficacité, du point de vue de la proportion de patients obtenant une réponse objective, et la toxicité d’un traitement combinant tafasitamab (un anticorps anti-CD19) et lénalidomide (durée médiane de suivi : 13,2 mois)
Therapeutics directed against CD19 have been tested in B-cell lymphomas during the past 20–30 years. Previous antibody approaches that have reached later stage development have included SAR3419, an anti-CD19 antibody–drug conjugate incorporating a maytansinoid as the cytotoxic chemotherapy, 1 and the anti-CD19 bispecific T-cell engager blinatumomab. 2 The antilymphoma activity of these monotherapies was promising, with objective response rates in the range of 25–45%, but further optimisation was required. CD19-directed chimeric antibody receptor (CAR) T-cell therapies have now become standard treatment options for patients with relapsed or refractory diffuse large B-cell lymphoma. The two commercially available drugs have objective response rates of 50–80%, with some patients continuing in long-term remission. The development of novel treatment approaches targeting CD19 in diffuse large B-cell lymphomas, as well as in other B-cell lymphomas, should now consider their potential effect on the rapidly evolving standards in the field of CAR T-cell therapy.
The Lancet Oncology , commentaire, 2019